• Explore /
  • Poster
  • / Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a U.S. community oncology network.

Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a U.S. community oncology network.

Abstract Poster

Authors

David Waterhouse

David Michael Waterhouse

US Oncology Research/Oncology Hematology Care (OHC), Inc., Cincinnati, OH

David Michael Waterhouse, Candice Yong, Nicholas J. Robert, Kathleen M. Aguilar, Juliet Ndukum, Yiqiong Xie, Brian S. Seal, Ion Cotarla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care

Track

Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities

Sub Track

Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 28; abstr 295)

DOI

10.1200/JCO.2020.39.28_suppl.295

Abstract #

295

Poster Bd #

E5

Abstract Disclosures

Similar Posters

First Author: Jarushka Naidoo

First Author: Lian Liu

First Author: Paromita Datta

First Author: John M. Varlotto